Log In
BCIQ
Print this Print this
 

T-Guard

  Manage Alerts
Collapse Summary General Information
Company Xenikos B.V.
DescriptionFusion protein linking anti-CD3 and anti-CD7 mAbs with ricin A toxin
Molecular Target T cell receptor (TCR) ; CD3
Mechanism of ActionApoptosis stimulator
Therapeutic ModalityBiologic: Fusion protein
Latest Stage of DevelopmentPhase I/II
Standard IndicationGraft-versus-host disease (GvHD)
Indication DetailsTreat graft-versus-host disease (GvHD)
Regulatory Designation U.S. - Orphan Drug (Treat graft-versus-host disease (GvHD));
EU - Orphan Drug (Treat graft-versus-host disease (GvHD))
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today